echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Cold Spring Harbor Laboratory reveals the mechanism of glioma, bringing new hope for the treatment of malignant brain tumors!

    Cold Spring Harbor Laboratory reveals the mechanism of glioma, bringing new hope for the treatment of malignant brain tumors!

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    *For medical professionals only

    Treatment strategies for BRD8 can be used to treat most patients with
    glioblastoma.


    Executive Summary


    On December 21, 2022, a new study published in the journal Nature revealed that BRD8 protein overactivity is an important cause of glioblastoma's pathogenesis, which provides new strategies
    for controlling, treating and even curing glioblastoma.

    Study screenshots


    status quo


    Glioblastoma (GBM), also known as glioblastoma multiforme, is a fast-growing and highly aggressive malignancy
    .
    According to statistics, the incidence of glioblastoma worldwide is about 3.
    2 per 100,000 people, and the number of
    new patients reaches 256,000 every year.

    The clinical symptoms of glioblastoma are mainly headache, vomiting, vision loss and incontinence, which seriously affect the quality of life
    of patients and families.
    With a median survival of only 12-14 months and a 5-year survival rate of less than 5%, glioblastoma patients remain one of
    the most difficult cancers to treat at the global level.
    This statistic has not improved
    for decades due to the lack of effective clinical treatment.


    P53 is a major component of the body's natural cancer defense system, which prevents cells from overgrowing and turning into tumors
    .
    Almost all cancers exhibit mutations and failures
    of P53.
    But curiously, while P53 is normally expressed in most GBM cases, GBM exhibits a tumor phenotype
    in which P53 is disrupted.


    conclusion


    The team led by Dr.
    Alea Mills, the first author of the study and professor at the Cancer Center of the Cold Spring Harbor Laboratory (CSHL) in the United States, found that the tumor transcriptomics data of 452 GBM patients found an important protein that regulates P53: bromodomain-containing protein 8 (BRD8).
    The molecular mechanism
    of BRD8 regulation of P53 was further analyzed by RNAseq and animal-level studies.

    The results of the study showed:
    • Among the 452 GBM patients who underwent transcriptomic analysis, 71% of patients had no mutation in P53 (P53WT), and compared with the mutant GBM patients, the target gene CDKN1A of P53 had loss of function, suggesting that regardless of whether P53 was mutated, the function of P53 protein in GBM patients was inhibited, and BRD8, the protein BRD8, which was most relevant to regulating P53 epigenetics, was mined through further database comparison.
    • BRD8 protein is abnormally active in glioblastoma, and inhibits P53 gene activity and weakens P53 protein function through the "lock and key mechanism" combined with unacetylated H2AZ, in other words, the presence of BRD8 protein will induce GBM;
    • When BRD8 is inactivated by genome editing, the unmutated P53 gene in GBM is reactivated and begins to stop tumor growth;
    • In animal tests, the P53 gene of GBM implanted in the brains of mice was "unlocked" when the BRD8 protein was inactivated, the tumors stopped growing, and the life span of mice was extended
      .

    prospect


    This study identified the mechanism by which BRD8 protein regulates P53 gene activity in GBM, which may provide an effective strategy
    for the treatment of P53WT GBM.

    Alea Mills noted:
    • With these findings, we can then design small molecules to disrupt this interaction, which may be used as a new therapeutic strategy for glioblastoma;
    • This treatment that targets the BRD8 gene is highly effective as long as the P53 gene in the patient's body is still functioning, and as far as we know, this is the case in about 71% of GBM patients
      .
      That is, treatment strategies targeting BRD8 can be used to treat most patients with
      glioblastoma.

    The web version of the doctor's station is online!
    Scan the QR code below or click to read the original article
    to view more oncology information without downloading



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.